We bring you the latest news from the healthcare about the health care in the United Kingdom.

dinsdag 10 april 2018

The Lancet: [News] Oncologists burnout in the spotlight

[News] Oncologists burnout in the spotlight
The newly appointed president of the Association of Community Cancer Centers in the USA for the term 2018–19, Thomas A Gallo (Virginia Cancer Institute, Richmond, VA, USA), has outlined his intention to make burnout the focus of his tenure.
Read more

[Comment] Targeting EZH2 with tazemetostat
Enhancer of zeste homolog 2 (EZH2) is a subunit of the chromatin remodelling polycomb repressive complex 2. EZH2 is a histone methyltransferase and trimethylates histone H3 lysine 27 (H3K27). EZH2 activation contributes to epigenetic transcriptional silencing because H3K27 methylation is a repressive histone modification.1 Physiologically, EZH2 activity is high in stem or progenitor cells, in which EZH2 represses genes associated with cell cycle arrest and promotes self-renewal. However, in differentiated cells EZH2 activity is opposed by the switch/sucrose non-fermentable (SWI/SNF) multiprotein complex, which promotes terminal differentiation and regulates self-renewal.
Read more

[Comment] A CRITICal period for chemoradiotherapy in gastric cancer
In western countries, there are two standards of care for adjuvant therapy of resectable gastric cancer: perioperative chemotherapy, as investigated in the UK Medical Research Council MAGIC trial,1 and postoperative chemoradiotherapy, as investigated in the US Intergroup 0116 (INT0116) trial.2 Over the past decade, clinical practice has varied depending on geographic location, with postoperative chemoradiation being practiced more commonly in North America, whereas European countries have mainly used perioperative chemotherapy.
Read more

[Articles] Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial
Postoperative chemoradiotherapy did not improve overall survival compared with postoperative chemotherapy in patients with resectable gastric cancer treated with adequate preoperative chemotherapy and surgery. In view of the poor postoperative patient compliance in both treatment groups, future studies should focus on optimising preoperative treatment strategies.
Read more

[Articles] Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
Tazemetostat showed a favourable safety profile and antitumour activity in patients with refractory B-cell non-Hodgkin lymphoma and advanced solid tumours, including epithelioid sarcoma. Further clinical investigation of tazemetostat monotherapy is ongoing in phase 2 studies in adults and a phase 1 study for children, which are currently enrolling patients who have B-cell non-Hodgkin lymphoma and INI1-negative or SMARCA4-negative tumours.
Read more